HIMS Hims & Hers Health
- 16.920
- +0.610+3.74%
- 16.870
- -0.050-0.30%
Hims & Hers Health News
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Cuts Target Price to $20
Citi Downgrades Hims & Hers Health(HIMS.US) to Hold Rating, Maintains Target Price $20
Hold Rating on Hims & Hers Health Amid Competitive Threats From Lilly's Zepbound
Needham Initiates Hims & Hers Health(HIMS.US) With Buy Rating, Announces Target Price $24
Hims & Hers Health Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS) and RxSight (RXST)
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $24
Leerink Partners Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Cuts Target Price to $21
Hold Rating on Hims & Hers Health Amid Revenue Uptick and Market Uncertainties
Seaport Global Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Raises Target Price to $28
Hims & Hers Health Analyst Ratings
A Quick Look at Today's Ratings for Hims & Hers Health(HIMS.US), With a Forecast Between $18 to $28
Piper Sandler Keeps Their Hold Rating on Hims & Hers Health (HIMS)
Hims & Hers Health: Strong Q2 Performance and Positive Outlook Reinforce Buy Rating
Hold Rating on Hims & Hers Health Amid GLP-1 Market Uncertainties and Competitive Pressures
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating
Truist Financial Sticks to Their Hold Rating for Hims & Hers Health (HIMS)
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Maintains Target Price $23
Truist Securities Adjusts Price Target on Hims & Hers Health to $23 From $13, Maintains Hold Rating
Hims & Hers Health Analyst Ratings
Analysis
Price Target
No Data
No Data